Skip to main content
OpenTrials
Completed

NCT Number: NCT02367001

Randomized Trial Evaluating the Effectiveness of the General Practitioner Involvement in Cancer Screening Invitations

Our goal is to evaluate, in France, the effectiveness (in terms of participation) of the general practitioner involvement (signature) and a more personalized communication in invitation letters to organized screening of breast, colorectal and cervical cancers.

The hypothesis on which this project is based is that communication is probably more effective if the "receiver" feels personally targeted by invitation letters (Dear Martin, I am writing ...) and if he knows "the issuer "(his general practitioner rather an unknown person).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Cervical Cancer Colonic Diseases Colorectal Cancer Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Gastrointestinal Diseases Gastrointestinal Neoplasms Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases Skin Diseases Skin and Connective Tissue Diseases Urogenital Diseases Urogenital Neoplasms Uterine Cervical Diseases Uterine Cervical Neoplasms Uterine Diseases Uterine Neoplasms

Age range

25 year–74 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre de Coordination des Dépistages des Cancers (CCDC)

Tours, 37044, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Living in Indre-et-Loire (french territorial division 37)
  • Be affiliated to the following three health insurance companies: CPAM (Caisse Primaire d'Assurance Maladie), MSA (Mutualité Sociale Agricole), or RSI (Régime social des Indépendants)
  • Having declared (to health insurance company) an attending physician who has given its written consent to participate in the study
  • Present no exclusion criterion to cancer screening ( for each one)
  • Be old from 50 to 74 years (breast and colorectal cancer) or from 25 to 65 years (cervical cancer)

Exclusion criteria

Treatment and study plan

Normal invitation

Other

No modification and signed by the coordinating doctor as usual

revised invitation signed by the coordinating doctor

Other

Invitation with revised text and layout and signed by the coordinating doctor as usual

Revised invitation signed by the attending physician

Other

signature typed or typed + handwritten

Primary outcomes

  1. Evaluate the effect on the participation (of the population) in cancer screening of an intervention involving the general practitioner (integration of signature) in the invitation letters

    Time frame: 9 or 12 months after the invitation letters

    The participation / non participation will be measured for each cancer screening (breast, colorectal and cervical) :

    • 9 months after the invitation letters for breast and colorectal cancers
    • 12 months after the invitation letters for cervical cancer

    The participation rate is defined as the number of people having participated, divided by the total number of people in the group or subgroup considered.

    Analysis by comparing the participation rates between groups (Group 1, Group 2 and Group 3) and sub-groups will be done.

Secondary outcomes

  1. Evaluate the effectiveness on the participation (of the population) of the use of a simplified and more focused communication in the invitation letters : comparison of the participation rates in arm 1 (normal invitation) and arm 2 (revised invitation)

    Time frame: 9 or 12 months after the invitation letters

  2. Evaluate the effectiveness on the participation (of the population) of the two types of general practitioner signature (typed versus typed + handwritten) by comparing the participation rates between two sub-groups in the arm 3.

    Time frame: 9 or 12 months after the invitation letters

  3. Cost-effectiveness of different strategies for each cancer screening (breast, colorectal and cervical) as measured by cost effectiveness ratio (total costs in Euros divided by total screened people)

    Time frame: 9 or 12 months after the invitation letters

Sponsors and collaborators

Lead sponsor

University Hospital, Tours

Other

Registry information

Official study title

Randomized Trial Evaluating the Effectiveness of a "Targeted Communication" With the General Practitioner Involvement in Cancer Screening Invitation Letters

Acronym: GPs

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Feb 20, 2015
Registry last updated
Oct 1, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.